Moberg Pharma AB (publ) (MOB) Q3 2020 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Moberg Pharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.755 Hello and welcome to the Mobag Pharma conference call. 00:00:03.755 -- 00:00:08.419 Throughout the call, all participants will be in listen-only mode and afterwards there 00:00:08.419 -- 00:00:13.304 will be a question and answer session. Just to remind you, this conference call is being 00:00:13.304 -- 00:00:18.049 recorded. Today I'm pleased to present the CEO, Anna Jung. 00:00:18.049 -- 00:00:20.609 Please begin your meeting. 00:00:21.092 -- 00:00:25.732 Thank you and hello. My name is Anna Jung and I'm the CEO of Mobag Pharma. 00:00:25.732 -- 00:00:30.237 I also have our VP of Finance, Mark Beveridge, with me on this call today. 00:00:30.237 -- 00:00:35.283 I'm happy to present our interim report for the fifth quarter since 00:00:35.283 -- 00:00:39.028 we had a prolonged year, July to September 2020. 00:00:39.028 -- 00:00:44.194 You can find the report on our web page and there you can also find a PowerPoint 00:00:44.194 -- 00:00:49.400 presentation that I will be using as the basis for this telephone 00:00:49.400 -- 00:00:55.914 meeting. So I will start on page three in that presentation 00:00:55.937 -- 00:00:59.822 with the brief introduction to mobile pharma. 00:00:59.822 -- 00:01:04.769 So we're a Swedish pharmaceutical company that based our products on drug delivery of 00:01:04.769 -- 00:01:09.956 known substances, which reduces time to market and development risk compared to traditional 00:01:09.956 -- 00:01:11.818 drug development. 00:01:11.818 -- 00:01:15.964 And our lead program is MOB15 against onychomycosis, 00:01:15.964 -- 00:01:20.368 nail fungus. the global sales potential of $250 to $500 00:01:20.368 -- 00:01:23.051 million annually. 00:01:23.051 -- 00:01:28.098 And based on the outcome of the two P3 trials on m...